Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

NCT05194072 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT05194072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05194072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
January 12, 2022
Completion date
May 14, 2025
Enrollment
250 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, carcinoma, non-small-cell lung, cholangiocarcinoma, endometrial neoplasms, fallopian tube neoplasms, gallbladder carcinoma, her2 negative breast neoplasms, hormone receptor positive breast neoplasms, ovarian neoplasms, peritoneal neoplasms, triple negative breast neoplasms